Literature DB >> 30536024

Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma.

Ryusei Matsuyama1, Daisuke Morioka2, Ryutaro Mori2, Yasuhiro Yabushita2, Seigo Hiratani2, Yohei Ota2, Takafumi Kumamoto2, Itaru Endo2.   

Abstract

BACKGROUND: The concept of "borderline resectable" was recently introduced to the field of surgery for pancreatic cancer, and surgical outcomes for this disease with extremely dismal prognosis have improved since the introduction of this concept. However, no such concept has yet been introduced to the field of surgery for hilar cholangiocarcinoma (HCca). AIM: To determine a definition and criteria for "borderline resectable" in the field of surgery for HCca. PATIENTS AND METHODS: Retrospective analysis of 88 patients undergoing curative-intent surgery for HCca at our institution between May 1992 and December 2008 to clarify independent prognostic factors.
RESULTS: Survival outcomes were obtained for these 88 patients, with a 5-year overall survival rate of 31.8%. Independent factors predictive of cancer death were determined by multivariate analysis to be the presence of regional lymph node metastasis (LNM) and pathological confirmed vascular invasion (VI). Cumulative survival rates of 23 patients with both LNM and VI who underwent surgery were significantly worse than those of the remaining 65 surgically treated patients and similar to those of 26 patients who were considered to have unresectable disease and treated with non-surgical multidisciplinary treatment during the same study period.
CONCLUSION: Outcomes of surgery for cases of HCca showing regional LNM and VI were no better than those of non-surgical treatment for unresectable disease. Coexistence of these two factors indicates oncologically dismal condition and thus such cases should be considered "borderline resectable." Treatments additional to surgery are required for "borderline resectable" cases to obtain better outcomes.

Entities:  

Mesh:

Year:  2019        PMID: 30536024     DOI: 10.1007/s00268-018-04883-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  45 in total

1.  Major hepatectomy for hilar cholangiocarcinoma type 3 and 4: prognostic factors and longterm outcomes.

Authors:  Olivier Baton; Daniel Azoulay; Delvart V René Adam; Denis Castaing
Journal:  J Am Coll Surg       Date:  2006-12-27       Impact factor: 6.113

2.  Preoperative evaluation of the longitudinal extent of borderline resectable hilar cholangiocarcinoma by intraductal ultrasonography.

Authors:  E Ryoung Choi; Yun Hee Chung; Jong Kyun Lee; Kyu Taek Lee; Kwang Hyuck Lee; Dong Wook Choi; Seong Ho Choi; Jin Seok Heo; Kee-Taek Jang; Sang Mo Park; Jae Hoon Lim
Journal:  J Gastroenterol Hepatol       Date:  2011-12       Impact factor: 4.029

Review 3.  Combined portal vein resection in the treatment of hilar cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  W Chen; K Ke; Y L Chen
Journal:  Eur J Surg Oncol       Date:  2014-02-28       Impact factor: 4.424

4.  Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma.

Authors:  Peter Neuhaus; Armin Thelen; Sven Jonas; Gero Puhl; Timm Denecke; Wilfried Veltzke-Schlieker; Daniel Seehofer
Journal:  Ann Surg Oncol       Date:  2011-10-01       Impact factor: 5.344

5.  Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma.

Authors:  Toshifumi Wakai; Yoshio Shirai; Tetsuya Moroda; Naoyuki Yokoyama; Katsuyoshi Hatakeyama
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

6.  Role of three-dimensional imaging in operative planning for hilar cholangiocarcinoma.

Authors:  Itaru Endo; Hiroshi Shimada; Mitsutaka Sugita; Yoshiro Fujii; Daisuke Morioka; Kazuhisa Takeda; Sadatoshi Sugae; Kuniya Tanaka; Shinji Togo; Holger Bourquain; Heinz O Peitgen
Journal:  Surgery       Date:  2007-11       Impact factor: 3.982

7.  Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.

Authors:  Ka Wing Ma; Tan To Cheung; Wong Hoi She; Kenneth Siu Ho Chok; Albert Chi Yan Chan; Wing Chiu Dai; Wan Hang Chiu; Chung Mau Lo
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

Review 8.  Hilar cholangiocarcinoma: current management.

Authors:  Fumito Ito; Clifford S Cho; Layton F Rikkers; Sharon M Weber
Journal:  Ann Surg       Date:  2009-08       Impact factor: 12.969

9.  Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasuo Hayashidani; Yasushi Hashimoto; Hiroaki Nakamura; Akira Nakashima; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2009-05-07       Impact factor: 3.452

10.  Comparative Analysis of Left- Versus Right-sided Resection in Klatskin Tumor Surgery: can Lesion Side be Considered a Prognostic Factor?

Authors:  Francesca Ratti; Federica Cipriani; Guglielmo Piozzi; Marco Catena; Michele Paganelli; Luca Aldrighetti
Journal:  J Gastrointest Surg       Date:  2015-05-08       Impact factor: 3.452

View more
  4 in total

1.  Transhepatic Direct Approach to the "Limit of the Division of the Hepatic Ducts" Leads to a High R0 Resection Rate in Perihilar Cholangiocarcinoma.

Authors:  Takehiro Noji; Kimitaka Tanaka; Aya Matsui; Yoshitsugu Nakanishi; Toshimichi Asano; Toru Nakamura; Takahiro Tsuchikawa; Keisuke Okamura; Satoshi Hirano
Journal:  J Gastrointest Surg       Date:  2021-01-05       Impact factor: 3.452

2.  Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Ryutaro Mori; Yohei Ota; Yuki Homma; Yasuhiro Yabusita; Seigo Hiratani; Takashi Murakami; Yu Sawada; Kentaro Miyake; Yasuhiro Shimizu; Takafumi Kumamoto; Itaru Endo
Journal:  Ann Surg Oncol       Date:  2022-01-07       Impact factor: 5.344

3.  Surgical outcomes of perihilar cholangiocarcinoma based on the learning curve of a single surgeon at a tertiary academic hospital: A retrospective study.

Authors:  Hye Jeong Park; Dai Hoon Han; Gi Hong Choi; Jin Sub Choi
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-02-28

4.  Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status.

Authors:  Naohisa Kuriyama; Masanobu Usui; Kazuaki Gyoten; Aoi Hayasaki; Takehiro Fujii; Yusuke Iizawa; Hiroyuki Kato; Yasuhiro Murata; Akihiro Tanemura; Masashi Kishiwada; Hiroyuki Sakurai; Shugo Mizuno; Shuji Isaji
Journal:  BMC Cancer       Date:  2020-05-11       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.